ArticleInflammopharmacology2026
Molecular docking-guided identification of multi-target anti-inflammatory phytochemicals from almond (Prunus dulcis) gum and experimental validation of almond gum-mediated silver/zinc oxide nanobiocomposites for accelerated wound healing.
Article in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Wound healing is a complex biological process where uncontrolled inflammation often delays tissue repair, imposing a significant clinical and economic burden worldwide. This study aimed to develop and evaluate almond gum (Prunus dulcis) based silver and zinc oxide nanobiocomposites (AG-Ag and AG-ZnO) through integrated computational, In-vitro and In-vivo studies as a promising therapeutic approach for accelerating wound healing. This study is the first to comparatively evaluate Ag-NPs and ZnO-NPs within the same almond gum matrix. A total of 31 phytoconstituents of Prunus dulcis were screened for ADME properties via pkCSM, and potential bioactive compounds were docked against COX-2, TNF-α, and VEGFR-2. Quercetin-3-diglucoside and Corosolic acid recorded the strongest binding affinities toward COX-2 (- 8.8 kcal/mol), mechanistically supporting the anti-inflammatory basis of Prunus dulcis. The green-synthesized nanobiocomposites were characterized via UV-Vis spectroscopy, FTIR, XRD, SEM, zeta sizer, and zeta potential, with mean particle sizes of 73.33 nm and 225.2 nm for AG-Ag and AG-ZnO, respectively. In-vitro studies revealed strong antioxidant activity, with AG-ZnO exhibiting the highest TPC (342.29 ± 1.18 µg GAE/g) and TFC (158.20 ± 0.40 µg CE/g), and AG-P the lowest DPPH IC50 (47.67 ± 2.01 µg/mL). Both nanobiocomposites further demonstrated potent antibacterial and anti-biofilm activities against Escherichia coli, Staphylococcus aureus, Klebsiella pneumoniae, and Bacillus subtilis, alongside significant anti-inflammatory activity and negligible hemolytic toxicity. In vivo evaluation using a rabbit excisional wound model demonstrated superior wound contraction with AG-Ag (90%) and AG-ZnO (93%) compared to the standard drug Polyfax (68%) and untreated control groups. Treatment groups also showed significant modulation of inflammatory biomarkers (ESR, CRP, IL-6) at Days 7 and 15 compared to controls. Histopathological studies showed active collagen deposition, fibroblast migration, and keratinocyte proliferation. These findings collectively concluded Prunus dulcis gum-stabilized Ag/ZnO nanobiocomposites as safe, mechanistically validated, and biocompatible candidates for advanced wound healing therapeutics.
Indexed as
Identifiers
42789219What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.